Beta-blockers with intrinsic sympathomimetic activity

Pharmacodynamics: How partial agonism works

From a pharmacological standpoint, drugs in this group (e.g., pindolol, oxprenolol, and bopindolol) are partial agonists of $\beta_1$- and $\beta_2$-adrenoceptors. This means their molecules exhibit a dual nature of interaction with targets.

The essence of the effect is as follows:

• Mild stimulation: The drug substance binds to adrenergic receptors and stimulates them. However, this stimulation is significantly weaker than that caused by natural, endogenous mediators of our body — adrenaline and noradrenaline.
• Competitive blockade: By occupying the receptors with its molecule, the drug physically blocks access for potent full agonists (catecholamines).

In classical pharmacology test questions, students are often asked to choose a drug with ISA from a list (e.g., propranolol, timolol, atenolol, pindolol). The correct answer in such a series will always be pindolol, as the other listed agents lack intrinsic sympathomimetic activity.

Two modes of action: Dependence on sympathetic tone

The uniqueness of beta-blockers with ISA lies in the fact that their final clinical effect directly depends on the current tone of the patient's sympathetic nervous system. The drug acts as a kind of "smart modulator", adapting to the body's stress level.

1. At high sympathetic tone (physical exertion, stress, anxiety):

A large number of potent catecholamines circulate in the blood. ISA-containing drugs act here as true $\beta$-blockers. They displace adrenaline from receptors and eliminate its hyperactive effect. As a result, myocardial contractility and heart rate (HR) decrease predictably.

1. At low sympathetic tone (resting state, sleep):

The level of endogenous adrenaline is minimal. Under these conditions, the drug's own weak stimulating activity comes to the fore. Due to this, the receptors are not "switched off" completely. Clinically, this manifests as the absence of pronounced bradycardia — the drugs practically do not reduce HR at rest. Cardiac output also drops to a much lesser extent compared to the use of "pure" (true) beta-blockers without ISA.

Safety profile and clinical application

The presence of intrinsic sympathomimetic activity gives these drugs a number of weighty advantages in their safety profile, especially when compared to non-selective beta-blockers without ISA.

Safety profile advantages:

• Reduced risk of bronchospasm: They have a lesser effect on bronchial smooth muscle tone. The risk of bronchospasm is not completely excluded, but it is significantly lower.
• Vascular protection: They demonstrate less effect on peripheral vascular tone, minimizing the likelihood of peripheral arterial spasm.
• Metabolic neutrality: They have a significantly lesser effect on the action of hypoglycemic agents, making them more predictable in concomitant carbohydrate metabolism disorders.

Indications for use: This group of drugs is traditionally used in cardiology practice to treat two main pathologies:

• Arterial hypertension.
• Angina pectoris.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Mechanism of interaction of full and partial agonists at the receptor level
• Comparative characteristics of cardiohemodynamics when using pure beta-blockers versus blockers with ISA
• Effect of beta-blockers on peripheral vascular resistance
• Features of beta-blocker use against the background of hypoglycemic therapy

Other topics in the section "Drugs Acting on Adrenergic Synapses"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.